Dagan R
Paediatric Infectious Diseases Unit, Soroka University Medical Centre, Beersheba, Israel.
Vaccine. 1993;11 Suppl 1:S43-5. doi: 10.1016/0264-410x(93)90159-u.
The results are reported of a nationwide prospective epidemiological study in Israel whose purpose was to provide a background for decisions regarding the need for Hib conjugate vaccinations. During the two study years, 344 patients < 13 years of age with a positive blood or cerebrospinal fluid culture for Hib were seen in 25 medical centres in which paediatric patients were hospitalized. The overall incidence of Hib disease was 34 per 100,000 persons < 5 years old, an incidence in the range of those reported for western Europe. Similarly, the incidence of meningitis was 18/100,000. During the first year of life, the incidence of Hib was 117/100,000 and 93% of all cases were < or = 24 months old. The age distribution of our patients resembles that of immunologically compromised populations or of persons living in less industrialized areas, but the incidence of disease is similar to that found in western Europe. The data presented justify the widespread use of conjugate Hib vaccines in Israel.
本文报告了以色列一项全国性前瞻性流行病学研究的结果，该研究旨在为有关Hib结合疫苗接种必要性的决策提供背景依据。在研究的两年期间，在25家收治儿科患者的医疗中心共诊治了344名13岁以下血培养或脑脊液培养Hib阳性的患者。Hib疾病的总体发病率为每10万名5岁以下儿童中有34例，这一发病率与西欧报告的发病率范围相当。同样，脑膜炎的发病率为18/10万。在出生后的第一年，Hib的发病率为117/10万，所有病例中有93%年龄小于或等于24个月。我们研究对象的年龄分布类似于免疫功能低下人群或生活在工业化程度较低地区的人群，但疾病发病率与西欧的发病率相似。所呈现的数据证明在以色列广泛使用Hib结合疫苗是合理的。
